MX365206B - Metodo para el tratamiento de la enfermedad de parkinson. - Google Patents
Metodo para el tratamiento de la enfermedad de parkinson.Info
- Publication number
- MX365206B MX365206B MX2015012561A MX2015012561A MX365206B MX 365206 B MX365206 B MX 365206B MX 2015012561 A MX2015012561 A MX 2015012561A MX 2015012561 A MX2015012561 A MX 2015012561A MX 365206 B MX365206 B MX 365206B
- Authority
- MX
- Mexico
- Prior art keywords
- parkinson
- disease
- treatment
- levopoda
- tolcapone
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 abstract 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 abstract 2
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
- 229960003337 entacapone Drugs 0.000 abstract 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960004603 tolcapone Drugs 0.000 abstract 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779357P | 2013-03-13 | 2013-03-13 | |
| PCT/IL2014/050261 WO2014141261A1 (en) | 2013-03-13 | 2014-03-13 | Method for treatment of parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015012561A MX2015012561A (es) | 2016-06-28 |
| MX365206B true MX365206B (es) | 2019-05-27 |
Family
ID=50513395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012561A MX365206B (es) | 2013-03-13 | 2014-03-13 | Metodo para el tratamiento de la enfermedad de parkinson. |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20160022573A1 (enExample) |
| EP (2) | EP3892266A1 (enExample) |
| JP (2) | JP6472391B2 (enExample) |
| KR (1) | KR102209353B1 (enExample) |
| CN (2) | CN105209029A (enExample) |
| AU (1) | AU2014229127B2 (enExample) |
| BR (1) | BR112015022390A8 (enExample) |
| CA (1) | CA2904838C (enExample) |
| CL (1) | CL2015002641A1 (enExample) |
| DK (1) | DK2968218T3 (enExample) |
| ES (1) | ES2889626T3 (enExample) |
| HR (1) | HRP20211442T1 (enExample) |
| HU (1) | HUE056006T2 (enExample) |
| IL (1) | IL266648B (enExample) |
| MX (1) | MX365206B (enExample) |
| PL (1) | PL2968218T3 (enExample) |
| PT (1) | PT2968218T (enExample) |
| RU (2) | RU2018144700A (enExample) |
| SG (2) | SG11201507538UA (enExample) |
| WO (1) | WO2014141261A1 (enExample) |
| ZA (1) | ZA201507621B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627655T3 (es) | 2009-05-19 | 2017-07-31 | Neuroderm Ltd | Composiciones para la administración continua de inhibidores de DOPA descarboxilasa |
| JP5902705B2 (ja) | 2010-11-15 | 2016-04-13 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
| PL2640370T3 (pl) | 2010-11-15 | 2018-09-28 | Neuroderm Ltd | Kompozycje do dostarczania przezskórnego substancji czynnych |
| PT3116475T (pt) * | 2014-03-13 | 2020-12-15 | Neuroderm Ltd | Composições de inibidores de dopa-descarboxilase |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| ES2973289T3 (es) | 2014-09-04 | 2024-06-19 | Lobsor Pharmaceuticals Ab | Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona |
| JP6567049B2 (ja) | 2014-10-21 | 2019-08-28 | アッヴィ・インコーポレイテッド | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| SMT202100247T1 (it) * | 2017-06-05 | 2021-05-07 | Dizlin Pharmaceuticals Ab | Soluzione per infusione di levodopa |
| WO2019097120A1 (en) * | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| WO2019147934A1 (en) * | 2018-01-29 | 2019-08-01 | Sackner Bernstein Jonathan | Methods for dopamine modulation in human neurologic diseases |
| JP2021517128A (ja) * | 2018-03-29 | 2021-07-15 | アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー | レボドパ分割用量組成物および使用 |
| CA3117983A1 (en) | 2018-11-15 | 2020-05-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| WO2022047298A1 (en) * | 2020-08-31 | 2022-03-03 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| WO2023282900A1 (en) * | 2021-07-08 | 2023-01-12 | Morehouse School Of Medicine | Method and system of diagnosing and treating neurodegenerative disease and seizures |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| KR101617990B1 (ko) * | 2005-06-08 | 2016-05-03 | 오리온 코포레이션 | 경구 용량 형태 |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| ES2627655T3 (es) * | 2009-05-19 | 2017-07-31 | Neuroderm Ltd | Composiciones para la administración continua de inhibidores de DOPA descarboxilasa |
| JP5902705B2 (ja) * | 2010-11-15 | 2016-04-13 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
-
2014
- 2014-03-13 JP JP2015562555A patent/JP6472391B2/ja active Active
- 2014-03-13 US US14/774,938 patent/US20160022573A1/en not_active Abandoned
- 2014-03-13 HU HUE14718177A patent/HUE056006T2/hu unknown
- 2014-03-13 WO PCT/IL2014/050261 patent/WO2014141261A1/en not_active Ceased
- 2014-03-13 SG SG11201507538UA patent/SG11201507538UA/en unknown
- 2014-03-13 CN CN201480027268.2A patent/CN105209029A/zh active Pending
- 2014-03-13 EP EP21176202.6A patent/EP3892266A1/en not_active Withdrawn
- 2014-03-13 EP EP14718177.0A patent/EP2968218B1/en active Active
- 2014-03-13 SG SG10201911731YA patent/SG10201911731YA/en unknown
- 2014-03-13 HR HRP20211442TT patent/HRP20211442T1/hr unknown
- 2014-03-13 CA CA2904838A patent/CA2904838C/en active Active
- 2014-03-13 CN CN201911315631.1A patent/CN110935026A/zh active Pending
- 2014-03-13 PT PT147181770T patent/PT2968218T/pt unknown
- 2014-03-13 ES ES14718177T patent/ES2889626T3/es active Active
- 2014-03-13 AU AU2014229127A patent/AU2014229127B2/en active Active
- 2014-03-13 MX MX2015012561A patent/MX365206B/es active IP Right Grant
- 2014-03-13 RU RU2018144700A patent/RU2018144700A/ru not_active Application Discontinuation
- 2014-03-13 BR BR112015022390A patent/BR112015022390A8/pt not_active Application Discontinuation
- 2014-03-13 KR KR1020157028984A patent/KR102209353B1/ko active Active
- 2014-03-13 DK DK14718177.0T patent/DK2968218T3/da active
- 2014-03-13 PL PL14718177T patent/PL2968218T3/pl unknown
- 2014-03-13 RU RU2015143112A patent/RU2677278C2/ru active
-
2015
- 2015-09-11 CL CL2015002641A patent/CL2015002641A1/es unknown
- 2015-10-13 ZA ZA2015/07621A patent/ZA201507621B/en unknown
-
2019
- 2019-01-22 JP JP2019008215A patent/JP6625773B2/ja active Active
- 2019-05-15 IL IL266648A patent/IL266648B/en active IP Right Grant
-
2020
- 2020-05-18 US US16/876,911 patent/US20210093560A1/en not_active Abandoned
-
2022
- 2022-03-18 US US17/698,189 patent/US20230047847A1/en not_active Abandoned
-
2024
- 2024-07-05 US US18/764,647 patent/US20250177292A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX365206B (es) | Metodo para el tratamiento de la enfermedad de parkinson. | |
| CY1120005T1 (el) | Συνεχης χορηγηση αναστολεων l-ντοπα, αποκαρβοξυλασης ντοπα, αναστολεων κατεχολ-ο-μεθυλ τρανσφερασης και συνθεσεις αυτων | |
| SA521421115B1 (ar) | عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2019007352A (es) | Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares. | |
| PH12015502788A1 (en) | Antibody formulations and methods | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| ECSP20011578A (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática | |
| PH12018501072A1 (en) | Modified release orally administered amino acid formulations | |
| NZ702730A (en) | Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments | |
| MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
| MX2024002360A (es) | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2022001565A (es) | Formas solidas de un estimulador de guanilato ciclasa soluble (sgc). | |
| MX384724B (es) | Regímenes de dosificación de melflufen para cáncer. | |
| PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
| MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
| BR112018007118A2 (pt) | método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem | |
| NZ712584A (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| HK1246687A1 (zh) | 治疗与帕金逊症治疗相关的运动失调及其副作用的方法 | |
| EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| IN2013MU03428A (enExample) | ||
| MX2016002139A (es) | Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |